USDA seeks EPA emergency exemption for engineered screwworm flies
The request, filed in November 2026, targets the U.S. cattle sector and hinges on EPA approval of a genetically engineered male-only screwworm strain.

The U.S. Department of Agriculture has asked the Environmental Protection Agency for an emergency use exemption for a genetically engineered male New World screwworm fly strain. The exemption would allow the agency to release the engineered males as a supplement to the existing sterile insect technique, which the USDA has already employed in the United States and Mexico to address a 2023 outbreak.
As of November 2026, more than 100 screwworm cases have been identified in the United States, a parasite that could cost the U.S. cattle industry billions of dollars per year. The current control program relies on a Panama-based facility that releases about 100 million sterile flies each week to keep the pest from moving northward. In 2023 the insects breached that barrier, prompting the USDA to begin domestic releases of sterile flies.
Researchers have engineered a male-only fly strain that carries a gene causing female offspring to die, eliminating the need to produce and sterilize females. The approach reduces feed, energy, and radiation requirements while improving population suppression. A separate line of research explores gene drives that spread a self-propagating gene designed to suppress or eradicate the species; Uruguay has approved caged-fly trials, but the technology has not yet been deployed in the wild.
The EPA exemption request highlights regulatory uncertainty. U.S. law does not clearly define gene drives, and agencies may apply different regulatory frameworks depending on the application. Ethical concerns about deliberately driving a species to extinction and the potential for gene-drive resistance add further complexity.
If granted, the exemption could increase eradication efficacy, lower operational costs, and provide a model for other pest-control programs. Policymakers will need to weigh the benefits against unresolved regulatory and ethical questions before authorizing field releases.
Further reading


